A lzheimer's disease (AD) and other dementias, major causes of morbidity and mortality in late life, have significant negative consequences on family caregivers and represent a huge economic burden on society. The Canadian Study of Health and Aging determined that 8% of Canadians who are age 65 years and over met criteria for dementia, with Objective: The objective of this paper is to review the randomized controlled trials (RCTs) on the pharmacotherapy of Alzheimer's disease and other dementias and to provide evidence-based recommendations for treatment of the cognitive impairment associated with these disorders.Method: A Medline search was conducted for RCTs, using the following key words: Alzheimer's disease, dementia, therapy, cholinesterase inhibitor, donepezil, rivastigmine, and galantamine. Studies were critically appraised, followed by a review of published major clinical practice guidelines. Recommendations for treatment were made based on best available evidence.
Results:The pharmacotherapy of Alzheimer's disease should include the meticulous management of vascular risk factors (for example, hypertension, diabetes, cholesterol, and stroke prophylaxis) and consideration for supplementation with folate, vitamin B complex, and vitamin E. Patients should be offered at least 1 trial of a cholinesterase inhibitor, with the possibility of another trial if the first is poorly tolerated or ineffective. Patients with vascular dementia and dementia with Lewy bodies should also be offered treatment with cholinesterase inhibitors. At this time, we lack sufficient data to recommend the use of hormone replacement or antiinflammatory therapy for treatment of dementia as the primary indication.
Conclusion:Reasonable evidence exists to provide recommendations for the pharmacotherapy of dementia. Treatment will likely result in modest but important benefits to patients, caregivers, and society. (Can J Psychiatry 2002;47:715-722) See page 720 for research funding and support and page 722 for author affiliations.
Clinical implications· Various pharmacologic treatment options are available for dementia. · Clinicians must constantly update their knowledge of this therapeutic area, given the significant number of studies published each year.
Limitations· Recommendations provided do not include nonpharmacologic treatment or management of behavioural disturbances and caregiver stress. · Important data are still missing about interventions, such as vitamin supplementation, hormone replacement, and antiinflammatory therapy. · Treatments that provide more than just modest benefits are urgently needed.